Listen on Apple Podcasts Badge
Spotify
AmazonMusic_button_black_RGB_5X
I heart media badge
stitcher logo
deezer-icon
Google Podcasts Badge
audible logo
castro-34
pocketcasts_small_light@2x
streaming-live-post-icon

3 Takeaways from my conversation with Deniz Kent, CEO of Prolific Machines:

1. Moonshot thinking starts with a real problem.
Deniz saw conflict over resources and asked: what if cells could make everything we need? That question built a company.

2. The best technology has the lowest cost AND highest quality.
When those two things align — adoption follows. Every time.

3. Assemble people smarter than you.
Deniz conceived the idea. Then got out of the way and hired scientists better than himself. That's leadership.

 

---

About Deniz Kent, PhD

• Co-Founder & CEO, Prolific Machines (Oct 2020–Present). Conceived the core technology, built the leadership team, and secured $90 M+ from top-tier investors including Breakthrough Energy Ventures, In-Q-Tel, Ki Tua Fund, Mayfield.

• GSK, Scientist (Sep 2014–Sep 2015). Developed in-vitro monocyte-derived dendritic cell models to investigate tolerogenic receptors.

• University of Bristol, Tumour Immunology Researcher (Sep 2014–Sep 2016). Investigated adenosinemediated suppression of CD8⁺ T cells.

• UMass Medical School, Visiting Scholar (Jun 2019–Dec 2019). Advanced collaborative research on hepatic cell models.

Domain expertise & credentials
• Conceived the vision for optogenetic bio- manufacturing and moved to the U.S. to co-found and lead Prolific Machines.

• PhD, Centre for Stem Cells & Regenerative Medicine, King’s College London (’16–’20). Co-discovered a novel human liver stem cell population (Segal & Kent et al., Nat Comm 2019). Led first high-throughput small-molecule screen on iPSC-derived hepatocytes—identifying 7 novel hits, 2 under patent.

• Technical specialties include optogenetics, single-cell RNAseq, iPSC differentiation, AI-driven bioprocess optimization Notable awards & recognitions

• Deniz is a member of Founder’s Pledge and was appointed to the World Economic Forum’s Bioeconomy Initiative.

*E - explicit language may be used in this podcast.